Luis Hidalgo, PhD, D(ABHI)

Associate Professor

  • Histocompatibility Lab Director
  • Division of Transplantation
(608) 265-0428

448 Science Drive
Madison WI 53711


  • PhD, Immunology, University of Alberta
  • Diplomate - American Board of Histocompatibility and Immunogenetics

Research Interests

The focus of my research laboratory aims at elucidating the various mechanisms used by the human immune system to damage transplanted organs with specific focus on antibody-mediated rejection (ABMR). The immunologic understanding of ABMR that we have thus far identified points to a limited number of players. These players include donor-specific antibodies (DSA) (primarily targeting HLA), endothelial cell targets, and NK cell and monocyte effector cells working in concert to maximize their damage.

The laboratory’s projects are therefore split into two principal areas: immune effector cells in ABMR, and endothelial cell biology. The immune effector projects have a strong focus on assessing immune function of NK cells and monocytes particularly as it relates to activation through their Fc-gamma receptors. Endothelial cell studies relate to endothelial susceptibility to immune damage in ABMR and regulation of HLA surface expression. Findings within either of these areas have clinical implications as all of our studies are based on human immunology using primary cells. Our ultimate goal is to identify donor and recipient characteristics that define immunologic risk beyond the limited characteristics currently used.

Recent Publications

  • Islet transplantation outcomes in type 1 diabetes and transplantation of HLA-DQ8/DR4: results of a single-centre retrospective cohort in Canada.
    Forbes S, Halpin A, Lam A, Grynoch D, Parker R, Hidalgo L, Bigam D, Anderson B, Dajani K, Kin T, O'Gorman D, Senior PA, Campbell P, Shapiro AMJ
    EClinicalMedicine 2024 Jan; 67: 102333
    [PubMed ID: 38169703]

  • The Banff 2022 Kidney Meeting Report: Reappraisal of microvascular inflammation and the role of biopsy-based transcript diagnostics.
    Naesens M, Roufosse C, Haas M, Lefaucheur C, Mannon RB, Adam BA, Aubert O, Böhmig GA, Callemeyn J, Clahsen-van Groningen M, Cornell LD, Demetris AJ, Drachenberg CB, Einecke G, Fogo AB, Gibson IW, Halloran P, Hidalgo LG, Horsfield C, Huang E, Kikić Ž, Kozakowski N, Nankivell B, Rabant M, Randhawa P, Riella LV, Sapir-Pichhadze R, Schinstock C, Solez K, Tambur AR, Thaunat O, Wiebe C, Zielinski D, Colvin R, Loupy A, Mengel M
    Am J Transplant 2024 Mar; 24(3): 338-349
    [PubMed ID: 38032300]

  • Antibody-mediated Rejection Without Detectable Donor-specific Antibody Releases Donor-derived Cell-free DNA: Results From the Trifecta Study.
    Halloran PF, Reeve J, Madill-Thomsen KS, Demko Z, Prewett A, Gauthier P, Billings P, Lawrence C, Lowe D, Hidalgo LG, the Trifecta Investigators
    Transplantation 2023 Mar 01; 107(3): 709-719
    [PubMed ID: 36190186]

  • Chronic Active Antibody-mediated Rejection in Kidney Transplant Recipients: Treatment Response Rates and Value of Early Surveillance Biopsies.
    Aziz F, Parajuli S, Jorgenson M, Garg N, Manchala V, Yousif E, Mandelbrot D, Hidalgo L, Mohamed M, Zhong W, Djamali A
    Transplant Direct 2022 Sep; 8(9): e1360
    [PubMed ID: 35935024]

  • Molecular diagnosis of ABMR with or without donor-specific antibody in kidney transplant biopsies: Differences in timing and intensity but similar mechanisms and outcomes.
    Halloran PF, Madill-Thomsen KS, Pon S, Sikosana MLN, Böhmig GA, Bromberg J, Einecke G, Eskandary F, Gupta G, Hidalgo LG, Myslak M, Viklicky O, Perkowska-Ptasinska A, INTERCOMEX Investigators
    Am J Transplant 2022 Aug; 22(8): 1976-1991
    [PubMed ID: 35575435]

All Publications on PubMed